Safety Alerts & Recalls

What does this mean?

Although a linkage between lung cancer and Exubera has not been established, Pfizer has nonetheless recommended that healthcare professionals and patients should seek alternative treatment options due to the limited availability of Exubera.

Updated safety information

Pfizer today informed healthcare professionals that it has updated safety information for Exubera, a short-acting insulin used to treat patients with diabetes.

The safety information has been updated to reflect new cases of lung cancer identified in clinical trial patients using Exubera, although there were too few cases to determine whether any linkage exists between these cases and Exubera treatment. All patients who were diagnosed with lung cancer had a prior history of cigarette smoking.

For more information, please visit: more information here

Source: Manufacturer
Publication Date: 2008-04-09
Last Updated: 2009-12-06
Share your story Share your story! Tell us how MediGuard has helped you or someone you love. Mobile graphic Download the MediGuard Mobile App to manage your prescription and over-the-counter medications, for free. Registration Info Taking multiple medications puts you at risk for possible drug-drug interactions Registration Info Monitor the medical treatment of you and your loved ones.
Back to Consumer Med Safety